Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
4(67%)
Results Posted
100%(2 trials)

Phase Distribution

Ph phase_3
1
17%
Ph phase_2
3
50%
Ph phase_1
2
33%

Phase Distribution

2

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Completed(2)

Detailed Status

Recruiting3
Completed2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 23 (50.0%)
Phase 31 (16.7%)

Trials by Status

active_not_recruiting117%
completed233%
recruiting350%

Recent Activity

4 active trials
Showing 5 of 6
completedphase_1

CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations

NCT04260529
recruitingphase_2

Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT

NCT04602377
completedphase_1

A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

NCT05383170
recruitingphase_2

Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.

NCT05563467
active_not_recruitingphase_2

OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

NCT04713514
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04260529Phase 1

CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations

Completed
NCT04602377Phase 2

Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT

Recruiting
NCT05383170Phase 1

A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

Completed
NCT05563467Phase 2

Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.

Recruiting
NCT04713514Phase 2

OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

Active Not Recruiting
NCT05085028Phase 3

A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Recruiting

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6